The consortium expects a whole-brain dataset by the end of next year
An international consortium of researchers has built a three-dimensional cellular atlas of the basal ganglia, the structures key to learning, controlling movement, making decisions and forming habits. The map draws on more than 25 million cells from humans, macaques and marmosets, and researchers say it could help identify cells involved in disease and guide more targeted medicines.
The basal ganglia are clusters of interconnected cells tucked beneath the cortex. Michael Hawrylycz, a senior investigator at the Allen Institute in Seattle, said, “It only occupies, in volume, about 2% of the brain.” The broader consortium is trying to map the entire brain, which contains more than 80 billion neurons.
Hongkui Zeng, director of brain science at the Allen Institute, said the basal ganglia are key to controlling movements, making decisions and forming habits. She said the structures are implicated in neurodegenerative diseases including Parkinson’s and Huntington’s, as well as diseases involving cognition or emotion, including schizophrenia, depression, bipolar and addiction.
The researchers selected the basal ganglia because the structure was important and evolutionarily conserved. Hawrylycz said, “We really wanted to choose a structure which was both important as well as evolutionarily conserved so that we could understand the difference between humans and other primates.” The basal ganglia are shared across many species, making them a starting point for the broader effort.
Consortium researchers looked at more than 25 million cells from the brains of humans, macaques and marmosets. They profiled where the cells were located, which of their genes were expressed and how the cells differed among people and animals. Zeng described the result: “So what you get is really a colorful map that shows all the cells, what kind of types they are and then where they are located.”
The atlas has three dimensions and layers of information. One layer is a heat map showing which cells express specific genes, including genes related to diseases like Parkinson’s or Alzheimer’s. Zeng said, “And if you know where they are, then you know, OK, those cells containing that gene probably play important roles in this disease.”
Cell Press published the atlas and more than two dozen accompanying papers as a package. It was the culmination of three years of scientific work, mainly funded by the National Institutes of Health, and involved researchers at more than 50 institutions around the world. Satrajit Ghosh, a senior scientist at the McGovern Institute for Brain Research at MIT, was among the participants.
Ghosh compared the effort to the Human Genome Project, launched in the ’90s, which gave scientists a common foundation for their research. He said, “Every neuroscientist has different feelings about what is important in the brain, but we need to consolidate information about how the parts of the brain exist, right?”
Talia Lerner, a basal ganglia researcher at the Center for Addiction and Mental Health in Toronto, said the atlas is a starting point for developing better drugs. Lerner was not affiliated with the research. In discussing treatments for Parkinson’s disease, she said, “One side effect of some of these medications can be increases in pathological gambling and other types of risk-seeking behavior.”
Lerner said more precise knowledge could make medicines more targeted: “The more that we can learn about this and, like, which function is where, the more I think we can make really targeted medicines that will have fewer side effects and will be able to help people more.”
Kamran Khodakhah, a neuroscientist at the Albert Einstein College of Medicine who was also not affiliated with the research, said the project produced a template for the entire brain. “What they have come up with is a template for the entire brain. So this - the same exact template and methodology can be used to look at other brain regions.”
The researchers describe the basal ganglia atlas as a crucial framework, and they say its methods and collaborations will help speed work on the rest of the brain. They expect to have a dataset for the whole brain by the end of next year and to publish in the next couple of years. Khodakhah said it would be remarkable if the researchers met that timetable and told them, “So good luck to them.”